Double-blind, placebo-controlled trial of octreotide long-acting repeatable (LAR) in thyroid-associated ophthalmopathy.

Dickinson AJ, Vaidya B, Miller M, Coulthard A, Perros P, Baister E, Andrews CD, Hesse L, Heverhagen JT, Heufelder AE, Kendall-Taylor P

The Journal of clinical endocrinology and metabolism1 Dec 2004Cited by 50 (Europe PMC)

PMID15579735DOI10.1210/jc.2004-0697PepBankPUB-15579735

Source link PubMedAsk about this study

Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanNon-randomized trialEfficacy outcome
In thyroid-associated ophthalmopathy, index changes were -1.12 with octreotide LAR versus -0.23 with placebo, with Wilcoxon P = 0.043 but covariance P = 0.16.
In plain wordsIn thyroid-associated eye disease, octreotide LAR reduced the index more than placebo by one test, but another test found no significant effect.
Peptide
Octreotide
Outcome
DecreaseOphthalmopathy index treatment effect
Study
n = 50
Comparator
Placebo
Outcome group
Eye Disease Activity · Eye
Studied dose
30 mg every 4 wk · 16 wkAs given in this study (human).
Measurements
Ophthalmopathy index change
−1.12 index points
octreotide LAR, weeks 0-16
Ophthalmopathy index change
−0.23 index points
placebo, weeks 0-16
Source sentences
Summary
The OI reduced by -1.12 in LAR (P = 0.0017) vs. -0.23 in placebo (P = 0.33), giving a barely significant treatment effect by Wilcoxon (P = 0.043), but analysis of covariance failed to confirm this (P = 0.16).
2 context sentences(design, population, supporting numbers)
Summary · context
Fifty euthyroid patients (11 males, 39 females; age 22-74 yr, median 50 yr) with active TAO
Summary · context
of median duration 0.9 yr received either 30 mg LAR or placebo every 4 wk for 16 wk; both groups then received 30 mg LAR for wk 16-32 and were followed up without treatment for a further 24 wk.
Report a problemFND-1557973505
02HumanNon-randomized trialEfficacy outcome
In thyroid-associated ophthalmopathy, neither group showed significant index change during weeks 16-32, when both received octreotide LAR.
In plain wordsIn thyroid-associated eye disease, neither group showed significant index change during weeks 16-32, when both received octreotide LAR.
Peptide
Octreotide
Outcome
No significant changeOphthalmopathy index during weeks 16-32
Study
n = 50
Comparator
Start of weeks 16-32
Outcome group
Eye Disease Activity · Eye
Studied dose
30 mg every 4 wk · 16 wk during weeks 16-32As given in this study (human).
Source sentences
Summary
During wk 16-32 there was no significant change in OI in either group.
2 context sentences(design, population, supporting numbers)
Summary · context
Fifty euthyroid patients (11 males, 39 females; age 22-74 yr, median 50 yr) with active TAO
Summary · context
of median duration 0.9 yr received either 30 mg LAR or placebo every 4 wk for 16 wk; both groups then received 30 mg LAR for wk 16-32 and were followed up without treatment for a further 24 wk.
Report a problemFND-1557973506
03HumanNon-randomized trialEfficacy outcome
In thyroid-associated ophthalmopathy, soft tissue inflammation decreased over weeks 0-32 in both treatment sequences, including the placebo-first sequence.
In plain wordsIn thyroid-associated eye disease, inflammation decreased from baseline over weeks 0-32 in both sequences, including placebo first.
Peptide
Octreotide
Outcome
DecreaseSoft tissue inflammation over weeks 0-32
Study
n = 50
Comparator
Baseline
Outcome group
Eye Disease Activity · Eye
Studied dose
30 mg every 4 wkAs given in this study (human).
Source sentences
Summary
The overall results (wk 0-32) showed reduction in STI and CAS in both groups.
2 context sentences(design, population, supporting numbers)
Summary · context
Fifty euthyroid patients (11 males, 39 females; age 22-74 yr, median 50 yr) with active TAO
Summary · context
of median duration 0.9 yr received either 30 mg LAR or placebo every 4 wk for 16 wk; both groups then received 30 mg LAR for wk 16-32 and were followed up without treatment for a further 24 wk.
Report a problemFND-1557973507
04HumanNon-randomized trialEfficacy outcome
In thyroid-associated ophthalmopathy, clinical activity scores decreased over weeks 0-32 in both treatment sequences, including the placebo-first sequence.
In plain wordsIn thyroid-associated eye disease, activity scores decreased from baseline over weeks 0-32 in both sequences, including placebo first.
Peptide
Octreotide
Outcome
DecreaseClinical activity score over weeks 0-32
Study
n = 50
Comparator
Baseline
Outcome group
Eye Disease Activity · Eye
Studied dose
30 mg every 4 wkAs given in this study (human).
Source sentences
Summary
The overall results (wk 0-32) showed reduction in STI and CAS in both groups.
2 context sentences(design, population, supporting numbers)
Summary · context
Fifty euthyroid patients (11 males, 39 females; age 22-74 yr, median 50 yr) with active TAO
Summary · context
of median duration 0.9 yr received either 30 mg LAR or placebo every 4 wk for 16 wk; both groups then received 30 mg LAR for wk 16-32 and were followed up without treatment for a further 24 wk.
Report a problemFND-1557973508
05HumanNon-randomized trialEfficacy outcome
In patients with thyroid-associated ophthalmopathy, soft tissue inflammation decreased significantly during weeks 0-16 with octreotide LAR and also decreased with placebo.
In plain wordsIn thyroid-associated eye disease, inflammation decreased from baseline with octreotide LAR and placebo during weeks 0-16.
Peptide
Octreotide
Outcome
DecreaseSoft tissue inflammation at weeks 0-16
Study
n: not reported in source
Comparator
Baseline
Outcome group
Eye Disease Activity · Eye
Studied dose
30 mg every 4 wk · 16 wkAs given in this study (human).
Source sentences
Summary
During wk 0-16 there was significant reduction in STI, subjective diplopia, and CAS in LAR-treated patients; STI and CAS were also reduced with placebo.
2 context sentences(design, population, supporting numbers)
Summary · context
Fifty euthyroid patients (11 males, 39 females; age 22-74 yr, median 50 yr) with active TAO
Summary · context
of median duration 0.9 yr received either 30 mg LAR or placebo every 4 wk for 16 wk; both groups then received 30 mg LAR for wk 16-32 and were followed up without treatment for a further 24 wk.
Report a problemFND-1557973501
06HumanNon-randomized trialEfficacy outcome
In patients with thyroid-associated ophthalmopathy, subjective diplopia decreased significantly from baseline during weeks 0-16 with octreotide LAR.
In plain wordsIn thyroid-associated eye disease, double vision decreased from baseline during weeks 0-16 with octreotide LAR.
Peptide
Octreotide
Outcome
DecreaseSubjective diplopia at weeks 0-16
Study
n: not reported in source
Comparator
Baseline
Outcome group
Eye Disease Activity · Eye
Studied dose
30 mg every 4 wk · 16 wkAs given in this study (human).
Source sentences
Summary
During wk 0-16 there was significant reduction in STI, subjective diplopia, and CAS in LAR-treated patients; STI and CAS were also reduced with placebo.
2 context sentences(design, population, supporting numbers)
Summary · context
Fifty euthyroid patients (11 males, 39 females; age 22-74 yr, median 50 yr) with active TAO
Summary · context
of median duration 0.9 yr received either 30 mg LAR or placebo every 4 wk for 16 wk; both groups then received 30 mg LAR for wk 16-32 and were followed up without treatment for a further 24 wk.
Report a problemFND-1557973502
07HumanNon-randomized trialEfficacy outcome
In thyroid-associated ophthalmopathy, clinical activity scores decreased significantly during weeks 0-16 with octreotide LAR and also decreased with placebo.
In plain wordsIn thyroid-associated eye disease, activity scores decreased from baseline with octreotide LAR and placebo during weeks 0-16.
Peptide
Octreotide
Outcome
DecreaseClinical activity score at weeks 0-16
Study
n: not reported in source
Comparator
Baseline
Outcome group
Eye Disease Activity · Eye
Studied dose
30 mg every 4 wk · 16 wkAs given in this study (human).
Source sentences
Summary
During wk 0-16 there was significant reduction in STI, subjective diplopia, and CAS in LAR-treated patients; STI and CAS were also reduced with placebo.
2 context sentences(design, population, supporting numbers)
Summary · context
Fifty euthyroid patients (11 males, 39 females; age 22-74 yr, median 50 yr) with active TAO
Summary · context
of median duration 0.9 yr received either 30 mg LAR or placebo every 4 wk for 16 wk; both groups then received 30 mg LAR for wk 16-32 and were followed up without treatment for a further 24 wk.
Report a problemFND-1557973503
08HumanNon-randomized trialEfficacy outcome
In thyroid-associated ophthalmopathy, the ophthalmopathy index changed by -1.12 from baseline with octreotide LAR (P = 0.0017).
In plain wordsIn thyroid-associated eye disease, the ophthalmopathy index decreased from baseline with octreotide LAR during weeks 0-16.
Peptide
Octreotide
Outcome
DecreaseOphthalmopathy index change at weeks 0-16
Study
n: not reported in source
Comparator
Baseline
Outcome group
Eye Disease Activity · Eye
Studied dose
30 mg every 4 wk · 16 wkAs given in this study (human).
Measurements
Ophthalmopathy index change
−1.12 index points
octreotide LAR, weeks 0-16, P = 0.0017
Source sentences
Summary
The OI reduced by -1.12 in LAR (P = 0.0017) vs. -0.23 in placebo (P = 0.33), giving a barely significant treatment effect by Wilcoxon (P = 0.043), but analysis of covariance failed to confirm this (P = 0.16).
2 context sentences(design, population, supporting numbers)
Summary · context
Fifty euthyroid patients (11 males, 39 females; age 22-74 yr, median 50 yr) with active TAO
Summary · context
of median duration 0.9 yr received either 30 mg LAR or placebo every 4 wk for 16 wk; both groups then received 30 mg LAR for wk 16-32 and were followed up without treatment for a further 24 wk.
Report a problemFND-1557973504

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:36 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.